Launches business unit to create AI psychiatrist focused on reducing inflammation

Vyome Holdings, Inc, a clinical-stage healthcare holding company, announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology. Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo’s assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI subcommittee comprised of Krishna Gupta, Mohanjit Jolly, and Stash Pomichter – all of whom are MIT alumni with deep AI expertise.

Health Technology Insights: Leo Cancer Care Raises $40 Million to Grow Upright Radiotherapy

“Inflammation is currently one of the biggest health crises facing humanity, and we intend to attack the condition from all angles in order to limit the usage of steroids,” said Stash Pomichter, a Director of Vyome. “We envision an AI psychiatrist that can diagnose and help treat systemic inflammation by targeting behavioral drivers and biomarkers.”

“The goal is to establish an entirely new therapeutic category at the intersection of mental health, psychoneuroimmunology, and digital health, with global commercialization beginning in the US and India. The team at Oculo has developed an innovative foundation of software and research, including on biomarkers such as ‘brain burn’ that are quite relevant to our focus at Vyome, and we are excited to build on this foundation,” added Pomichter.

Health Technology Insights: Prescryptive Earns HITRUST Certification for Data Security

The Oculo transaction will have no bearing on the progress of Vyome’s core biotech assets. Vyome remains funded through 2026 to progress its core business.

“We launched Oculo to build at the intersection of the human body and the human mind, and to quantify the workings of the mind by taking advantage of the latest advances in AI,” said Alay Shah, founder of Oculo. “I’ve always believed the best AI products would be built firmly with humans in the loop and I’m excited Vyome will carry forth this vision as they target inflammation.”

“The market size for digital therapeutics, especially ones that can reduce the reliance on biologics or other drugs, could end up being greater than $100B over the next decade,” said Mohanjit Jolly, a Director at Vyome and Partner at Iron Pillar, a firm with several AI related investments in the US and India. “The advances in AI create an opportunity to use data to better human lives across the board, but our focus is on reducing inflammation in every part of the body. It is one of the biggest health issues facing our society and leads to significant reliance on harmful drugs. I’m excited we were able to close this transaction with Oculo to launch our AI efforts in addition to advancing our existing inflammation-focused biotech assets.”

Health Technology Insights: Net Health to Build Largest Patient Outcomes Platform for Rehab Therapy Providers

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source- businesswire